Bionoxx Inc.
PrivateLast Round
Series B
Mar 21, 2023
Total Funding Raised
$17.26M
Company Overview
Bionoxx Inc. is a biotechnology company that develops neutrophil-directed T cell modulation technology to fight cancer and immune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bionoxx Inc. Comparables
Compare Bionoxx Inc. with similar companies based on industry and business-model similarity.
Bionoxx Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 21, 2023 | ||||
| Series B | Apr 1, 2019 |
Bionoxx Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DA Value Investment | Series B |
| ROI Investment Partners | Series B |
| Yuanta Investment | Series B |
| ID Ventures | Series B |
| Daekyo Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 27, 2024
Grew 36% QoQ, from 11 to 15 employees.
- Oct 20, 2024
Grew 27% QoQ, from 11 to 14 employees.
Bionoxx Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Bionoxx Inc.'s valuation, stock price, and market status.